VCD-597 / VetDC - LARVOL DELTA

Pathway therapeutics completes $4.5 million financing for novel PI3K inhibitor portfolio (Businesswire) -

Funding will be used to advance Pathway Therapeutics’ lead dual inhibitor of PI3 kinase alpha & mTOR (PWT33597) to clinic in 2011

Pipeline update

Study of PWT33597 mesylate in subjects with advanced malignancies (clinicaltrials.gov) - P1, N=72; Recruiting; New P1 trial

New trial • Oncology